950 million.
That is the single oddest number in Moderna’s latest 10‑Q. On paper the company walked into the quarter with a healthier looking balance sheet, cash of $1.7 billion, up 34.7% from a year earlier, and a slightly smaller operating loss (‑$815M versus ‑$907M). The topline barely moved: revenue was $145.0M, up 2.1%.
"This was primarily driven by a decrease in cash, cash equivalents and current investments of $661 million to fund operations, an increase in accrued liabilities of $523 million, largely driven by the $950 million litigation settlement accrual partially offset by lower spend in the period, and a $196 million increase in deferred revenue..."
Moderna / 10‑Q 2026‑07‑31
The filing makes the plumbing clear: a big liability popped into accrued liabilities, which mechanically reduced reported cash used in operations and boosted the headline cash balance versus the prior year. That $950 million figure is an accounting lever, not a new revenue stream.
"This reduction was primarily due to lower clinical trial expenses of $76 million, personnel-related costs and stock-based compensation of $27 million, and outside services of $18 million..."
Moderna / 10‑Q 2026‑07‑31
Moderna also trimmed its burn. R&D and trial spending fell as the company winds down several late‑stage programs. Those line‑item savings shaved hundreds of millions from operating outflows and helped narrow the quarterly loss, but they come from program timing, not a sudden lift in demand.
"Excluding these expenses, cost of sales and cost of sales as a percentage of net product sales and stand-ready manufacturing revenue for the six months ended June 30, 2026 decreased by 59% and 65 percentage points, respectively...primarily due to lower unutilized manufacturing capacity costs and losses on firm purchase commitments, partially offset by higher sales volume."
Moderna / 10‑Q 2026‑07‑31
Margins improved where it matters to the income statement, but the filing is explicit: the gain is driven by lower unutilized capacity costs and fewer write‑downs on purchase commitments. In short, better utilization and fewer one‑off losses, not a jump in products sold.
A few other plumbing details matter. Net cash used in operating activities fell sharply, helped by the accrual change; investing cash flows fell because proceeds from maturities and sales of marketable securities were far lower this period. Inventory grew faster than revenue and diluted shares increased 2.6% year over year, small but not invisible.
Moderna still sits with scale and partners. The filing notes ongoing work with Merck on mRNA‑4157 across multiple Phase 2 and Phase 3 trials, which keeps future upside tied to pipeline outcomes rather than current product sales.
The single concrete next check: Moderna’s next quarterly cash‑flow filing, which should show whether the $950 million accrual turns into a cash payment, gets paid down gradually, or is adjusted back. That will be the clearest test of how much of this quarter’s "improvement" was timing and accounting.
The quarter traded trial spend and an accrual for a cleaner cash story; revenue barely moved.
Source: Moderna 10‑Q filed 2026‑07‑31.